Diagnostic, treatment & behavioural interventions to reduce MRSA colonisati

Lead Research Organisation: University of Birmingham
Department Name: Immunity and Infection

Abstract

We will use our knowledge of the way in which MRSA colonises and spreads from patient to patient to design innovative methods of prevention and thereby reduce MRSA infection in hospitals

Technical Summary

MRSA colonisation is one of the major challenges facing the NHS. Colonisation of patients by MRSA invariably precedes infection and transmission from both colonised and infected patients leads to outbreaks. We will identify the key organism and patient factors responsible for colonisation and apply innovative new methods to eliminating carriage and, by behavioural modification, transmission. The impact of these interventions will be carefully evaluated by expert economic and operational modellers.

Publications

10 25 50
 
Description Healthcare link analysis tool 
Organisation Quadrant Visual Solutions
Country United Kingdom 
Sector Private 
PI Contribution A UKCRC Strategic Development Grant (SDG) enabled our newly formed consortium (MIRACOL group) to forge links with another SME - Quadrant Visual Solutions - to develop a proposal for a link analysis tool capable of immediate translation in a number of healthcare settings. This proposal was detailed in a UKCRC Translational Infection Research Initiative outline application. The application was short-listed and MIRACOL was invited to submit a full application.
Impact Our UKCRC outline application was short-listed and MIRACOL was invited to submit a full application. The collaboration with Quadrant Visual Solutions will result in the development of a link analysis tool capable of immediate translation in a number of healthcare settings.
Start Year 2009
 
Description MRSA specific bacteriophage therapy 
Organisation Novolytics Ltd
Country United Kingdom 
Sector Private 
PI Contribution A UKCRC Strategic Development Grant (SDG) enabled our newly formed consortium (MIRACOL group) to strengthen links with Novolytics to develop future research which was included in a UKCRC Translational Infection Research Initiative outline application. The application was short-listed and MIRACOL was invited to submit a full application.
Impact Our UKCRC outline application was short-listed and MIRACOL was invited to submit a full application. The proposed research involving Novolytics will enhance the understanding of the effects of phage therapy compared to mupirocin in the decolonisation of S. aureus from patients in hospitals.
Start Year 2007